| Literature DB >> 33712571 |
Xin Li1,2, Shengdan Nie3, Ziyang Lv2, Lingran Ma2, Yuxi Song2, Zhongxu Hu1, Xin Hu2, Zhiqiang Liu1, Gaoya Zhou4, Zhijie Dai5, Tao Song6, Jiajia Liu7, Shan Wang8.
Abstract
In order to set up a reliable prediction system for the tumor grade and prognosis in glioma patients, we clarify the complicated crosstalk of Annexin A2 (ANXA2) with Glypican 1 (GPC1) and demonstrate whether combined indexes of ANXA2 and GPC1 could improve the prognostic evaluation for glioma patients. We found that ANXA2-induced glioma cell proliferation in a c-Myc-dependent manner. ANXA2 increased the expression of GPC1 via c-Myc and the upregulated GPC1 further promoted the c-Myc level, forming a positive feedback loop, which eventually led to enhanced proliferation of glioma cells. Both mRNA and protein levels of ANXA2 were upregulated in glioma tissues and coincided with the overexpression of GPC1. Besides, we utilized tissue microarrays (TMAs) and immunohistochemistry to demonstrate that glioma patients with both high expression of ANXA2 and GPC1 tended to have higher rate of tumor recurrence and shorter overall survival (OS). In conclusion, the overexpression of ANXA2 promotes proliferation of glioma cells by forming a GPC1/c-Myc positive feedback loop, and ANXA2 together with its downstream target GPC1 could be a potential "combination biomarker" for predicting prognosis of glioma patients.Entities:
Year: 2021 PMID: 33712571 PMCID: PMC7954792 DOI: 10.1038/s41419-021-03547-5
Source DB: PubMed Journal: Cell Death Dis Impact factor: 8.469